Global contract research organization (CRO) providing specialty laboratory services to support the entire drug development cycle.
USA, CAN, BE, AUS, CHN
Joined November 2011
- Tweets1.4K
- Following1.1K
- Followers1K
- Likes719
Announcement! CellCarta and Tivenix are expanding their partnership.
Tivenix's AI-powered platform applies bioinformatics to the epigenetic analysis of cell-free DNA and other tissue-derived signals, supporting precision medicine applications.
Read here: buff.ly/L8RIN9p
Did we miss you in Basel? We're still available to chat! 馃憢
We're always excited to discuss the biggest challenges facing your programs, from translational research to CDx commercialization. If we missed you in Basel, send us a message to connect 鉁夛笍 buff.ly/0gMp5PK
CellCarta's Christopher Ung is the Conference Chair for this afternoon's World CB and CDx Summit sessions.
Join him for two engaging sessions covering diverse topics across clinical biomarkers and CDx development.
See you there!
We're pleased to announce a strategic partnership with Waters Corporation to advance companion diagnostics (CDx) development. buff.ly/CRDVBPf
The collaboration creates a framework to jointly pursue CDx and next-generation flow cytometry opportunities with biopharma.
including through our laboratory in China.
"By combining CellCarta's end-to-end laboratory capabilities with Waters' diagnostic and CDx development expertise, and flow cytometry platforms, we can help sponsors reduce complexity, preserve program continuity
and make earlier, more informed decisions about how to scale their programs." Todd Chermak, President, CellCarta
Read the full release: buff.ly/CRDVBPf
We're bringing the CellCarta team to Basel for an afternoon built around your biomarker challenges.
Spaces are limited, so reserve yours here: buff.ly/eUmM6Kl
馃搮Oct 7, 12:10 PM
Presentation: The CDx Model Needs to Change. What China taught us about breaking silos, moving faster and going global
馃搮Oct 8, 11:20 AM,
Presentation: Can AI Predict ADC Response? With Siraj A. of Lunit, on discovering, validating and deploying AI biomarkers faster
If you'd rather talk through your own program, the CellCarta team will be in Boston all week. Book here: buff.ly/g38Az8B
CellCarta and Imagene AI are expanding their collaboration to give biopharma a coordinated path to validate, deploy and scale AI-powered biomarker and companion diagnostic (CDx) programs.
Read the full announcement: buff.ly/EVKyNo0
Our experts head to Basel, Switzerland next month! Join us for a day of insights into biomarkers- multimodal science, practical paths to CDx development, and regulatory support to take them from innovation to impact.
Register here: buff.ly/KzWdXxt
Big News! Following recent updates to the FAMHP Q&A on in-house IVDs, CellCarta can provide EU clinical trial testing through an additional regulatory pathway under IVDR Article 5(5) when study conditions are met.
Learn more here: buff.ly/fNxmgb9
We're en-route to San Diego! Will we see you there?
Don't miss the presentation on a major hot-topic, leveraging digital pathology and AI in research and clinical trials.
Book a meeting with the team to learn more: buff.ly/wbPgm4e
Join us at the World CB & CDx Summit! Discover how early alignment and parallel development between CRO and diagnostic partners can accelerate program timelines, based on lessons we've learned working on therapeutic programs in China.
Don't miss out! buff.ly/goVogsY
We're excited to share our latest Let's Talk interview, featuring a conversation between Christopher Ung and Dr. Zhou Caicun, lung cancer expert and principal investigator of the HARMONi-2 trial.
The full talk is live now! buff.ly/m111wT7